Business
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Canada NewsWire ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n New partnerships and contracts expected to bring in over\n \n $1 million\n \n in near-term R&D/milestone revenue and generate long term commercial revenue\n \n \n \n \n \n \n SUNNYVALE, Calif.\n \n \n ,\n \n \n Aug. 8, 2023\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended\n \n June 30, 2023\n \n , reporting further progress in its commercial expansion.\n \n \n \n \n \n \n \n \n \n \"The second quarter was marked by significant further progress in our commercial buildout and portfolio diversification with new agreements signed, multiple new partnerships under discussion and with two contracts in late-stage negotiations,\" said Dr.\n \n Chris Savile\n \n , Willow's President & CEO. \"This growing demand for our R&D capabilities led us to cost effectively move to larger new lab and office facilities in July to accommodate an increased pipeline of projects.\"\n \n \n Willow's unaudited consolidated interim financial statements and related management's discussion and analysis for the quarter ended\n \n June 30, 2023\n \n , are available on SEDAR at\n \n www.sedarplus.ca\n \n .\n \n \n \n Highlights for the Quarter\n \n \n \n \n Closed three new contracts/partnerships during the quarter expected to bring in over\n \n \n \n $1 million\n \n in near-term R&D/milestone revenue and, if successful, generate long-term commercial revenue.\n \n \n Engaged in discussions regarding multiple partnerships with two related contracts in late-stage negotiations. The Company is seeing significant opportunities arise as it expands its enzyme engineering and supply capabilities and due to at least one larg...